SARS-CoV-2 RNAemia infrequent in blood donors

SARS-CoV-2 RNAemia infrequent in blood donors

Nucleic acid testing of donor plasma minipools (MPs) indicates that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNAemia is infrequent, according to a study published online May 27 in Transfusion.

Sonia Bakkour, Ph.D., from the Vitalant Research Institute in San Francisco, and colleagues tested collected from March 7 to Sept. 25, 2020, for SARS-CoV-2 RNA (vRNA) in donor plasma MPs of six or 16 donations. To estimate , reactive MPs were tested by transcription-mediated amplification after serial dilution.

Overall, 17,995 MPs corresponding to about 258,000 donations were tested for vRNA. The researchers identified three confirmed reactive MP16s, for an estimated prevalence of 1.16/100,000 vRNA reactive donations. The vRNA-reactive samples were not reactive for antibody; within each MP, the estimated viral loads of the (presumed single) positive donations ranged from <1,000 to <4,000 copies/mL. No infectivity was seen in inoculated permissive cell cultures when tested.

"Other studies have shown that in rare cases where a blood sample tested positive, transmission by blood transfusion has not occurred," Bakkour said in a statement. "Therefore, it appears safe to receive blood as a transfusion recipient and to keep donating blood, without fear of transmitting COVID-19 as long as current screenings are used."

Two authors disclosed ties to Grifols Diagnostic Solutions.

Explore further

Screening blood donations for Zika virus is costly, low yield

More information: Abstract/Full Text (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Citation: SARS-CoV-2 RNAemia infrequent in blood donors (2021, June 3) retrieved 6 December 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors